Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHDZ | ISIN: AU0000043945 | Ticker-Symbol: PBN
Frankfurt
21.11.24
08:08 Uhr
0,001 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0010,00412:51

Aktuelle News zur ALTERITY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary1
DiALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
DiALTERITY THERAPEUTICS LIMITED: Change of Company Secretary1
12.11.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium2
12.11.ALTERITY THERAPEUTICS LIMITED: ATH Presentation Tracking MSA Progression at Intl Symposium2
06.11.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH4342
ALTERITY THERAPEUTICS Aktie jetzt für 0€ handeln
06.11.Health Check: Prestigious publication supports Alterity's 'iron overload in brain' thesis1
04.11.ALTERITY THERAPEUTICS LIMITED: Alterity Announces Publication On ATH434 Mechanism of Action-
31.10.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
31.10.ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q1 FY25 Quarterly Cash Flow Report92Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial showing...
► Artikel lesen
31.10.ALTERITY THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report2
23.10.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
23.10.ALTERITY THERAPEUTICS LIMITED: Notice of Annual General Meeting-
15.10.Alterity Therapeutics nimmt am Maxim Healthcare Summit teil-
15.10.Alterity Therapeutics to join Maxim Healthcare Summit5
14.10.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 20243
14.10.ALTERITY THERAPEUTICS LIMITED: ATH to Participate in 2024 Maxim Healthcare Virtual Summit1
11.10.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting1
11.10.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
11.10.ALTERITY THERAPEUTICS LIMITED: Alterity Presents Data Describing Neuroprotection of ATH4342
Seite:  Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1